Endologix Named Outstanding Company in Medical Technology by TechAmerica

Jun 04, 2010, 09:00 ET from Endologix, Inc.

IRVINE, Calif., June 4 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that TechAmerica has named Endologix as Orange County's Outstanding Company in Medical Technology. The award was presented to Endologix at the 17th Annual TechAmerica High-Tech Innovation Awards on June 2, 2010 in Irvine, CA.  

John McDermott, President and CEO, said, "It is an honor to receive this award from TechAmerica. It is a testament to the hard work of all our employees and their dedication to our mission to be the leading innovator of treatments for aortic disorders. In the years ahead, we expect to introduce additional new technologies that will further improve patient outcomes and increase the adoption of our growing portfolio of aortic devices."

About TechAmerica Orange County

TechAmerica is the largest resource for technology companies in the United States and is the industry's leading trade association. TechAmerica Orange County serves the high-tech business interests of companies located in the region by providing access to opportunities for networking, business development, education and advocacy. Now in its 17th year, the TechAmerica High-Tech Innovation Awards is a premier business event that celebrates excellence and achievement in the region's technology industry, and honors local companies, individuals and products that drive innovation in Orange County.  

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink® System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's Web site at www.endologix.com.

Forward-Looking Statements

Except for historical information contained herein, this news release contains forward-looking statements, the accuracy of which are necessarily subject to risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Endologix. Many factors may cause actual results to differ materially from anticipated results, including the success of sales efforts for the Powerlink System and related new products, product research and development efforts, and other economic, business, competitive and regulatory factors. The Company undertakes no obligation to update its forward looking statements. Please refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2009, and the Company's other filings with the Securities and Exchange Commission, for more detailed information regarding these risks and other factors that may cause actual results to differ materially from those expressed or implied.

COMPANY CONTACT:

INVESTOR CONTACTS:

Endologix, Inc.

The Ruth Group

John McDermott, CEO

Nick Laudico (646) 536-7030

(949) 595-7200

Zack Kubow (646) 536-7020

www.endologix.com

SOURCE Endologix, Inc.



RELATED LINKS

http://www.endologix.com